We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Effectiveness of Point-of-Care Diagnostics for Schistosomiasis, Reviewed

By LabMedica International staff writers
Posted on 16 Mar 2015
Findings from an independent review of studies suggests that currently available point-of-care (POC) tests are significantly less reliable than conventional microscopy, emphasizing the need for development of better and affordable POC diagnostics for schistosomiasis (bilharzia), classified as a neglected tropical diseases (NTD).

Simpler, more rapid POC tests with sufficient accuracy could replace microscopy for diagnosing schistosomiasis. More...
The review was conducted by researchers from the Cochrane Infectious Diseases Group hosted at the Liverpool School of Tropical Medicine (LSTM; Liverpool, UK) to estimate accuracy of the circulating antigen (CA) test for urinary schistosomiasis and intestinal schistosomiasis, and of urine reagent (URStrip) tests for urinary schistosomiasis.

Two independent authors identified and assessed 90 studies involving almost 200,000 people, with 88 of the studies from field settings in Africa. Studies compared POC tests to microscopy as reference standard: for Schistosoma haematobium—microscopy of urine prepared by filtration, centrifugation, or sedimentation; for S. mansoni—microscopy of stool by Kato-Katz thick smear.

Among the URStrip tests for urinary schistosomiasis, those for detecting blood (microhaematuria) were more accurate than those for detecting protein (proteinuria) or white cells (leukocyturia). Sensitivity and specificity estimates: for blood 75% and 87%; for protein 61% and 82%; for white cells 58% and 61%, respectively.

For urinary schistosomiasis, CA test performance was worse (39% sensitivity, 78% specificity) than URStrips for blood. For intestinal schistosomiasis, CA test detected many infections identified by microscopy but wrongly labeled many uninfected people as infected (89% sensitivity, 55% specificity).

“The simple test using a strip for testing blood in the urine worked well. The antigen tests for the disease did not work so well for urinary schistosomiasis, and in intestinal schistosomiasis it may classify many uninfected people as infected and lead to unnecessary treatment,” said lead author Dr. Eleanor Ochodo, Stellenbosch University.

LSTM’s Prof. Russell Stothard, international expert in schistosomiasis and director of the new COUNTDOWN research consortium, which will trial and evaluate new approaches to drug distribution in NTD program, said: “Those in the field of NTD research and control welcome reviews of this kind, looking at the efficacy of diagnostic tests for diseases affecting some of the poorest communities in the world. They draw together largely fragmented literature into one place, allowing quick appraisal for informed decision-making. Reviews such as this will ensure that COUNTDOWN benefits from the best research intelligence from within the NTD community and stays well informed throughout.”

The review, by Ochodo EA et al., was published online March 11, 2015, in Cochrane Database of Systematic Reviews.

Related Links:

Cochrane Infectious Diseases Group
Liverpool School of Tropical Medicine (LSTM)



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.